SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BarryH who wrote (2121)10/5/1997 11:01:00 AM
From: sam   of 6136
 
As of June 30, 1997 (pre split), AGPH had 75,000,000 shares authorized, 14,714,960 shares issued and outstanding. Page 24 of the 1997 Annual Report. But the shares used in computing net loss per common share were 13,473,000. Pages 23 - 25. Assuming we now have twice as many shares post split, there are 29,429,920 shares issued and outstanding, and 26,946,000 shares shares used in computing pro-forma net loss (more or less). Page 23.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News